Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis;Natalizumab y reducción de los niveles de proteínas carboniladas en pacientes con esclerosis múltiple

Revista de Neurologia

Volumn 54, Issue 8, 2012, Pages 449-452

  Tasset, Inmaculada ^a   Agüera, Eduardo ^b   Gascón, Félix ^c   Giraldo, Ana I ^a   Salcedo, Manuel ^a   Cruz, Antonio H ^c   Sánchez, Fernando ^b   Túnez, Isaac ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

Antioxidant system; Carbonylated proteins; Multiple sclerosis; Natalizumab; Oxidative stress; Peripheral bio markers

Indexed keywords

ANTIOXIDANT; CARBONYL DERIVATIVE; NATALIZUMAB; PROTEIN; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; HUMAN; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; OXIDATION; OXIDATIVE STRESS; THERAPY EFFECT; ADULT; BLOOD; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; PROTEIN CARBONYLATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROTEIN CARBONYLATION;

EID: 84861304149     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5408.2011672     Document Type: Article

References (18)

1. Ruggiero V. Involvement of IL-1R/TLR signalling in experimental autoimmune encephalomyelitis and multiple sclerosis. Curr Mol Med 2011; Oct 27 [Epub ahead of print].
2. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 2012; 45: 26-30.
3. Bowie A, O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000; 59: 13-23.
4. Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Arbizu T, Izquierdo G, et al. Spanish consensus on the use of natalizumab (Tysabri ®)-2011. Neurología 2011; Nov 9 [Epub ahead of print].
5. Midaglia L, Muñoz-García D, Sopeña B, Rodríguez-Cerdeira C. Infección cutánea por Mycobacterium marinum en un paciente en tratamiento con natalizumab. Rev Neurol 2011; 52: 701-702.
6. Horga A, Castilló J, Río J, Tintoré M, Auger C, Sastre-Garriga J, et al. Estudio observacional sobre la efectividad y seguridad del natalizumab en el tratamiento de la esclerosis múltiple. Rev Neurol 2011; 52: 321-330
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
8. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846.
9. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990; 186: 464-478.
10. Flohé L, Günzler WA. Assays of glutathione peroxidase. Methods Enzymol 1984; 105: 114-121.
11. Pennisi G, Cornelius C, Cavallaro MM, Salinaro AT, Cambria MT, Pennisi M, et al. Redox regulation of cellular stress response in multiple sclerosis. Biochem Pharmacol 2011; 82: 1490-1499.
12. Tavazzi B, Batocchi A P, Amorini AM, Nociti V, D'Urso S, Longo S, et al. Serum metabolic profle in multiple sclerosis patients. Mult Scler Int 2011; 2011: 167156.
13. Liu Y, Liu J, Tetzlaf W, Paty DW. Cynader MS. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic Biol Med 2006; 40: 960-967.
14. Leung G, Sun W, Zheng L, Brookes S, Tully M, Shi R. Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune encephalomyelitis mouse. Neuroscience 2011; 173: 150-155.
15. Farooqui T, Farooqui AA. Lipid-mediated oxidative stress and inflammation in the pathogenesis of Parkinson's disease. Parkinsons Dis 2011; 2011: 247467.
16. Gu Y, Dee CM, Shen J. Interaction of free radicals, matrix metalloproteinases and caveolin-1 impacts blood-brain barrier permeability. Front Biosci (Schol Ed) 2011; 3: 1216-1231.
17. Hosokawa T, Nakajima H, Doi Y, Sugino M, Kimura F, Hanafusa T, et al. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier. J Neuroimmunol 2011; 236: 81-86.
18. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, et al. Te effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009; 16: 528-536.